CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 6 enrolled
Drug / intervention
Azilsartandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02451150
NCT02451150Phase 3Completed
CompareCT.gov

An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics Following a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension

Takeda·interventional·Posted May 21, 2015·Updated Apr 7, 2016

In Brief

A Phase 3 clinical trial evaluating Azilsartan for Pediatric Hypertension. Completed, enrolled 6 participants across 3 sites.

Detailed Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of TAK-536 (azilsartan) in pediatric patients aged 6 to less than 16 years with hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Hypertension
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 21, 2015
Enrollment StartAug 1, 2015
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.1 years ago

Interventions

Azilsartandrug

Azilsartan tablets